Search is Powered by Google
Transplants / Organ Donations News

Roche's Organ-Rejection Drug CellCept Increases Risk Of Birth Defects, Miscarriage, FDA Says

Main Category: Transplants / Organ Donations
Also Included In: Pregnancy / Obstetrics;  Women's Health / Gynecology;  Pediatrics / Children's Health
Article Date: 01 Nov 2007 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.

FDA issued a new black box warning to the drug's label about the increased risk of ear and facial deformities -- as well as problems in limbs, the heart and other organs -- among fetuses and infants exposed to the drug (Reuters, 10/29). FDA cited National Transplantation Pregnancy Registry data published in December 2006 of 24 women who were exposed to CellCept. The women had a total of 33 pregnancies, of which 15 resulted in a miscarriage and 18 in a live birth. Among the 18 live births, four infants had birth defects, according to Dow Jones. According to postmarketing data, which were collected by Roche and involved 77 women who took CellCept, there were 25 miscarriages and 14 defects among fetuses and infants. Six of the defects were ear abnormalities (Corbett Dooren, Dow Jones, 10/29).

In addition, FDA said the drug, which is known generically as mycophenolate mofetil, might lower blood levels of the hormones in oral contraceptives, making the pills less effective at preventing pregnancy. FDA said women of childbearing age should have a negative pregnancy test within one week before beginning treatment with CellCept, receive birth control counseling and use effective contraception (AP/Google.com, 10/29).

Roche sent a letter to physicians explaining the new warnings (Dow Jones, 10/29). According to FDA, prehuman trials of the drug found some signs of fetal defects (Reuters, 10/29).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on CellCept.





Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Stem Cell Treatment For Crohn's Disease
21 Feb 2009
Cellular therapy with stem cells is revolutionizing the focus of treatment of many serious diseases. Replacing the cells of damaged tissue with other new cells from the same patient is already a reality...


Running Tips
Running Tips

Beginning a running program may seem daunting at first, but it is a gradual process. Fitness expert Jonathan Cane provides tips for beginning runners.

more videos are available in our health videos section.